Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
ILA-C52H8 | Cynomolgus | Cynomolgus IL-2 R alpha / CD25 Protein, His Tag (MALS verified) |
|
||
ILA-H82F9 | Human | Biotinylated Human IL-2 R alpha / CD25 Protein, Fc,Avitag™ (MALS verified) |
|
||
ILA-C52H4 | Canine | Canine IL-2 R alpha / CD25 Protein, His Tag |
|
||
ILA-M52H9 | Mouse | Mouse IL-2 R alpha / CD25 Protein, His Tag |
|
||
ILA-H82E6 | Human | Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade |
|
||
ILA-H52H9 | Human | Human IL-2 R alpha / CD25 Protein, His Tag |
|
||
ILA-H5251 | Human | Human IL-2 R alpha / CD25 Protein, Fc Tag (MALS verified) |
|
Biotinylated Human IL-2 R alpha, His,Avitag, premium grade (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).
Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Arthritis, Juvenile; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Lymphoma; Iritis; Uveitis; Thrombocytopenia; Rejection in heart transplantation; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Retinal Diseases; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; HTLV-I Infections; Myelodysplastic Syndromes; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Leukemia; Granulomatosis with Polyangiitis; HIV Infections; Diabetes Mellitus, Type 1 | Details |
Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Kidney Diseases; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic | Details |
Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Arthritis, Juvenile; Leukemia, T-Cell; Behcet Syndrome; Melanoma; Lymphoma; Iritis; Uveitis; Thrombocytopenia; Rejection in heart transplantation; Uveitis, Anterior; Colitis, Ulcerative; Asthma; Breast Neoplasms; Psoriasis; Multiple Sclerosis, Relapsing-Remitting; Retinal Diseases; Radiation Injuries; Carcinoma, Ductal; Rejection of organ transplantation; Multiple Sclerosis; HTLV-I Infections; Myelodysplastic Syndromes; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Leukemia; Granulomatosis with Polyangiitis; HIV Infections; Diabetes Mellitus, Type 1 | Details |
Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Anemia, Aplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Kidney Failure, Chronic; Uveitis; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Emphysema; Pulmonary Disease, Chronic Obstructive; Colitis, Ulcerative; Primary Myelofibrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rejection of renal transplantation; Multiple Myeloma; Rejection of organ transplantation; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Hodgkin Disease; Kidney Diseases; Keratoplasty rejection; Hemoglobinuria, Paroxysmal; Cytokine Release Syndrome; Leukemia, Myelogenous, Chronic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals Plc | Graft vs Host Disease | Details |
Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 3 Clinical | Alkermes Plc | Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma | Details |
Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
PT-101 | PT-101; MK-6194; PT101 | Phase 2 Clinical | Pandion Therapeutics | Lupus Erythematosus, Systemic; Colitis, Ulcerative; Dermatitis, Atopic; Vitiligo | Details |
LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Melanoma | Details |
Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Myeloproliferative Disorders; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myelodysplastic Syndromes; Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma | Details |
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic | Details |
Vopikitug | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
XmAb-564 | XmAb-564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Psoriasis; Dermatitis, Atopic | Details |
IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Dermatitis, Atopic | Details |
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Institute Of Hematology & Blood Diseases Hospital | Details | |||
Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals Plc | Graft vs Host Disease | Details |
Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 3 Clinical | Alkermes Plc | Ovarian Neoplasms; Solid tumours; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Melanoma | Details |
Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
PT-101 | PT-101; MK-6194; PT101 | Phase 2 Clinical | Pandion Therapeutics | Lupus Erythematosus, Systemic; Colitis, Ulcerative; Dermatitis, Atopic; Vitiligo | Details |
LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Leukemia, Hairy Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Skin Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Melanoma | Details |
Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Myeloproliferative Disorders; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Myelodysplastic Syndromes; Ovarian Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma | Details |
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia; Leukemia, Lymphoid; Celiac Disease; Paraparesis, Tropical Spastic; Leukemia, Large Granular Lymphocytic | Details |
Vopikitug | RO-7296682; RG-6292 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
XmAb-564 | XmAb-564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Psoriasis; Dermatitis, Atopic | Details |
IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Lupus Vulgaris; Dermatitis, Atopic | Details |
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Institute Of Hematology & Blood Diseases Hospital | Details |
This web search service is supported by Google Inc.